Ethical Pharmaceuticals Market - Growth, Trends, Covid-19 Impact, and Forecasts (2022 - 2027)

The Ethical Pharmaceuticals Market is Segmented by Type (Lipid Regulators, ACE Inhibitors, Respiratory Agents, Narcotic Analgesics, Diuretics, Calcium Antagonists, Hormonal Contraceptives, Others), Application (Hospitals and Clinics, Others), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The report offers the value (in USD million) for the above segments.

Market Snapshot

Ethical Pharmaceuticals Market Forecast
Study Period: 2019-2027
Base Year: 2021
Fastest Growing Market: North America
Largest Market: Asia-Pacific
CAGR: 10.5 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

The Ethical Pharmaceuticals Market is expected to register a CAGR of 10.5% during the forecast period (2022-2027).

Covid-19 has significantly impacted the ethical pharmaceuticals market due to the rising consumption of drugs related to the respiratory system. For instance, in the Journal of American Pharmacist Association, titled 'The global impact of COVID-19 on drug purchases: A cross-sectional time-series analysis' in December 2021, Before COVID-19, the monthly number of standardized pharmaceutical units per 100 people ranged from 3990 to 4760. Compared to 2019, the number of units of pharmaceuticals purchased increased by 15% to 5309.3 per 100 people in March 2020. Furthermore, according to the same source, in the early months of the COVID-19 pandemic, there was evidence of global medicine stockpiling, particularly among developed countries.

The major factors driving the market growth include the rise in the burden of chronic diseases such as diabetes, cancers, and hypertension, the rise in the geriatric population, the rise in product launches for ethical drugs, increase in research and development collaborations to develop novel ethical pharmaceuticals, among others.

The rise in chronic disease is among the major factors driving the market growth. For instance, according to the International Diabetic Federation 2021, diabetes affects around 537 million persons aged 20 to 79. By 2030, the overall number of diabetics is expected to reach 643 million, and by 2045, it will reach 783 million. Furthermore, according to Globocan 2020, there were 19,292,789 new cancer cases seen in 2020 across the globe, and 9,958,133 deaths were reported globally in 2020. Such a huge burden of chronic diseases will lead to increased adoption of ethical medication, driving the market growth significantly.

Furthermore, the rise in collaborations to develop novel drugs has further driven the market growth due to the development and entry of novel drugs into the market. For instance, in March 2020, Curadev Pvt. Ltd. and Bayer entered research cooperation and license agreement for Curadev's Stimulator of Interferon Genes (STING) antagonist program. The collaboration aims to find new therapeutic candidates for the treatment of lung, cardiovascular, and other inflammatory illnesses.

However, the patent expiry of current ethical pharmaceuticals and the lengthy approval process for these drugs are expected to hinder the market growth.

Scope of the Report

As per the scope of this report, Ethical Pharmaceuticals, often known as prescription drugs, can only be supplied by a pharmacist if a medical practitioner has issued a prescription for them. These are the categories of licensed pharmaceuticals regulated by various laws to prevent drug misuse and harmful side effects. The Ethical Pharmaceuticals Market is Segmented by Type (Lipid Regulators, ACE Inhibitors, Respiratory Agents, Narcotic Analgesics, Diuretics, Calcium Antagonists, Hormonal Contraceptives, Others), Application (Hospitals and Clinics, Others), and Geography (North America, Europe, Asia-Pacific, Middle East, and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 countries across major global regions. The report offers the value (USD million) for the above segments.

By Drug Class
Lipid Regulators
ACE Inhibitors
Respiratory Agents
Narcotic Analgesics
Diuretics
Calcium Antagonists
Hormonal Contraceptives
Others
By Application
Hospitals and Clinics
Others (Pharmaceutical Company, Contract Drug Manufacturing Organization)
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle-East and Africa
GCC
South Africa
Rest of Middle-East and Africa
South America
Brazil
Argentina
Rest of South America

Report scope can be customized per your requirements. Click here.

Key Market Trends

Hospitals and Clinics Segment Is Expected To Hold A Major Share In The Market Over The Forecast Period.

The Hospital and Clinics segment is expected to hold a major share in the ethical pharmaceuticals market and continue to do the same over the forecast period.

Due to an increase in hospital admissions due to huge population segments contracting the virus, the tendency to acquire medications prescribed by healthcare providers has increased dramatically. This boosted the broader ethical drug business by increasing product demand.

The rise in hospital admissions is expected to drive market growth. Furthermore, Covid-19 has further impacted the market growth due to the rise in hospital admissions during the pandemic. For Instance, in January 2022, according to the American Academy of Pediatrics and the Children's Hospital Association, weekly COVID-19 cases in children surpassed 300,000 for the first time since the pandemic began. As of December 31, the new COVID-related hospital admissions rate had hit a new high of 0.74 per 100,000 children. The high rise in hospital admissions due to COVID-19 fuelled the market growth during the pandemic.

Furthermore, the rise in hospitals is further expected to fuel the market growth. For instance, according to the Organisation for Economic Co-operation and Development updated in May 2022, the number of hospitals in Colombia in 2019 was 10,635 and increased to 10,899 in 2020. Such a rise in hospitals will lead to a rise in hospital admissions, driving the market growth over the forecast period.

Therefore, the factors above are expected to drive this segment's growth over the forecast period.

Ethical Pharmaceuticals Market Trends

North America Is Expected To Hold A Major Share And Expected To Show The Same Pace Over The Forecast Period

North America is expected to hold a major share in the market studied, and it is expected to do the same over the forecast period.

According to the American Hospital Association Hospital Statistics 2022, the number of all hospitals in the United States in 2022 was 6,093. Furthermore, according to the same source, total hospital admissions in the United States are 33,356,853. Such a huge number of hospitals and hospital admissions in the United States will drive the market growth due to the rise in the adoption of ethical drugs under the supervision of physicians, driving the market growth.

The rise in launches of ethical pharmaceuticals in the United States is further expected to drive market growth due to the rise in the adoption of such pharmaceuticals. For instance, in January 2021, the United States Food and Drug Administration approved VERQUVO, a soluble guanylate cyclase (sGC) stimulator, to reduce the risk of cardiovascular death and heart failure hospitalization.

Furthermore, in September 2021, the United States Food and Drug Administration (FDA) approved premix Norepinephrine Bitartrate in 5% Dextrose Injection developed by Baxter International Inc. in adult patients with severe, acute hypotension, norepinephrine is used to raise blood pressure (low blood pressure). Such launch of ethical drugs will lead to increased adoption of such drugs driving the market growth.

Moreover, according to the study published in the American Journal of Health-System Pharmacy, titled 'National trends in prescription drug expenditures and projections for 2020' in May 2020, Overall prescription drug spending is expected to rise from 4.0 percent to 6.0 percent in 2020, with rises of 9.0 percent to 11.0 percent in clinics and 2.0 percent to 4.0 percent in hospitals, respectively. Such a rise in prescription drug expenditure is further expected to propel market growth.

Therefore, the abovementioned factors are expected to drive the market growth in North America over the forecast period.

Ethical Pharmaceuticals Market Analysis

Competitive Landscape

The Ethical Pharmaceuticals market is moderately competitive as per the analysis, owing to a few companies currently dominating the market. The market is driven majorly due to the rise in product launches for various indications, research collaborations for the development of novel therapeutics, rise in the distribution of prescription drugs, among others. Some major players dominating the market include Sanofi, Amgen Inc, Merck & Co., Inc, GlaxoSmithKline plc, Novartis AG, and Pfizer Inc, among others.

Recent Development

  • In March 2022, the United States Food and Drug Administration approved one of the first generic Symbicort (budesonide and formoterol fumarate dihydrate) inhalation aerosols for the treatment of pulmonary health conditions.
  • In February 2022, the United States Food and Drug Administration (FDA) approved Jardiance (empagliflozin) 10 mg to reduce the risk of cardiovascular death and hospitalization for heart failure in adults.

Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Assumptions and Market Definition

    2. 1.2 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Rising Burden of Chronic Diseases and Increase in Geriatric Population

      2. 4.2.2 Rise in Research Activities For the Development of Novel Ethical Medicines

    3. 4.3 Market Restraints

      1. 4.3.1 Patent Expiry of Current Ethical Pharmaceuticals

      2. 4.3.2 Lengthy Approval Process

    4. 4.4 Porter's Five Forces Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION (Market Size by Value - USD million)

    1. 5.1 By Drug Class

      1. 5.1.1 Lipid Regulators

      2. 5.1.2 ACE Inhibitors

      3. 5.1.3 Respiratory Agents

      4. 5.1.4 Narcotic Analgesics

      5. 5.1.5 Diuretics

      6. 5.1.6 Calcium Antagonists

      7. 5.1.7 Hormonal Contraceptives

      8. 5.1.8 Others

    2. 5.2 By Application

      1. 5.2.1 Hospitals and Clinics

      2. 5.2.2 Others (Pharmaceutical Company, Contract Drug Manufacturing Organization)

    3. 5.3 Geography

      1. 5.3.1 North America

        1. 5.3.1.1 United States

        2. 5.3.1.2 Canada

        3. 5.3.1.3 Mexico

      2. 5.3.2 Europe

        1. 5.3.2.1 Germany

        2. 5.3.2.2 United Kingdom

        3. 5.3.2.3 France

        4. 5.3.2.4 Italy

        5. 5.3.2.5 Spain

        6. 5.3.2.6 Rest of Europe

      3. 5.3.3 Asia-Pacific

        1. 5.3.3.1 China

        2. 5.3.3.2 Japan

        3. 5.3.3.3 India

        4. 5.3.3.4 Australia

        5. 5.3.3.5 South Korea

        6. 5.3.3.6 Rest of Asia-Pacific

      4. 5.3.4 Middle-East and Africa

        1. 5.3.4.1 GCC

        2. 5.3.4.2 South Africa

        3. 5.3.4.3 Rest of Middle-East and Africa

      5. 5.3.5 South America

        1. 5.3.5.1 Brazil

        2. 5.3.5.2 Argentina

        3. 5.3.5.3 Rest of South America

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 Amgen Inc

      2. 6.1.2 AbbVie Inc

      3. 6.1.3 Johnson & Johnson

      4. 6.1.4 Eli Lilly and Company

      5. 6.1.5 Merck & Co., Inc

      6. 6.1.6 GlaxoSmithKline plc

      7. 6.1.7 Sanofi

      8. 6.1.8 Novartis AG

      9. 6.1.9 Abbott Laboratories

      10. 6.1.10 Otsuka Holdings

      11. 6.1.11 F. Hoffmann-La Roche Ltd

      12. 6.1.12 Teva Pharmaceutical Industries Ltd.

      13. 6.1.13 Pfizer Inc

      14. 6.1.14 Takeda Pharmaceutical Company

    2. *List Not Exhaustive
  7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Global Ethical Pharmaceuticals Market market is studied from 2019 - 2027.

The Global Ethical Pharmaceuticals Market is growing at a CAGR of 10.5% over the next 5 years.

North America is growing at the highest CAGR over 2021- 2026.

Asia-Pacific holds highest share in 2021.

Novartis AG, Abbott, Sanofi, GlaxoSmithKline plc, Merck & Co., Inc are the major companies operating in Global Ethical Pharmaceuticals Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!